Arrowhead Research | ARWR - Operating Profit


Arrowhead Research reported $-141.26M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
TG Therapeutics USD 34.8M 15.7M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026